CO2022013638A2 - Enzimas para la sialilación de glicanos - Google Patents

Enzimas para la sialilación de glicanos

Info

Publication number
CO2022013638A2
CO2022013638A2 CONC2022/0013638A CO2022013638A CO2022013638A2 CO 2022013638 A2 CO2022013638 A2 CO 2022013638A2 CO 2022013638 A CO2022013638 A CO 2022013638A CO 2022013638 A2 CO2022013638 A2 CO 2022013638A2
Authority
CO
Colombia
Prior art keywords
sialylation
glycans
enzymes
vector
nucleic acid
Prior art date
Application number
CONC2022/0013638A
Other languages
English (en)
Inventor
Iii James Meador
Sandra Freitas Pavao Sipsey
Amy Medeiros
Srishti Gurnani
Original Assignee
Momenta Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Momenta Pharmaceuticals Inc filed Critical Momenta Pharmaceuticals Inc
Publication of CO2022013638A2 publication Critical patent/CO2022013638A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/1048—Glycosyltransferases (2.4)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/1048—Glycosyltransferases (2.4)
    • C12N9/1081—Glycosyltransferases (2.4) transferring other glycosyl groups (2.4.99)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C12N15/625—DNA sequences coding for fusion proteins containing a sequence coding for a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/1048—Glycosyltransferases (2.4)
    • C12N9/1051—Hexosyltransferases (2.4.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y204/00—Glycosyltransferases (2.4)
    • C12Y204/01—Hexosyltransferases (2.4.1)
    • C12Y204/01022—Lactose synthase (2.4.1.22)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y204/00—Glycosyltransferases (2.4)
    • C12Y204/01—Hexosyltransferases (2.4.1)
    • C12Y204/01038—Beta-N-acetylglucosaminylglycopeptide beta-1,4-galactosyltransferase (2.4.1.38)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y204/00—Glycosyltransferases (2.4)
    • C12Y204/99—Glycosyltransferases (2.4) transferring other glycosyl groups (2.4.99)
    • C12Y204/99001—Beta-galactoside alpha-2,6-sialyltransferase (2.4.99.1)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

En la presente descripción se describen proteínas de fusión, p. ej., proteínas de fusión que comprenden porciones enzimáticamente activas de ST6Gal1 o B4GalT1, así como métodos para producirlas, molécula(s) de ácido nucleico que codifican la(s) proteína(s) de fusión, vector(es) que comprenden las moléculas de ácido nucleico, y célula(s) huésped(es) que comprenden el(los) vector(es). También se describen en la presente descripción métodos para sializar anticuerpos de inmunoglobulina G (IgG).
CONC2022/0013638A 2020-02-25 2022-09-22 Enzimas para la sialilación de glicanos CO2022013638A2 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202062981293P 2020-02-25 2020-02-25
US202063026927P 2020-05-19 2020-05-19
PCT/US2021/019607 WO2021173797A1 (en) 2020-02-25 2021-02-25 Enzymes for sialylation of glycans

Publications (1)

Publication Number Publication Date
CO2022013638A2 true CO2022013638A2 (es) 2022-10-21

Family

ID=77490192

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2022/0013638A CO2022013638A2 (es) 2020-02-25 2022-09-22 Enzimas para la sialilación de glicanos

Country Status (11)

Country Link
US (1) US20230303984A1 (es)
EP (1) EP4110391A1 (es)
JP (1) JP2023515554A (es)
KR (1) KR20220145877A (es)
CN (1) CN115605230A (es)
AU (1) AU2021226352A1 (es)
BR (1) BR112022016948A2 (es)
CA (1) CA3173252A1 (es)
CO (1) CO2022013638A2 (es)
MX (1) MX2022010467A (es)
WO (1) WO2021173797A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20240043838A (ko) * 2022-09-27 2024-04-04 크리포 주식회사 주요 아미노산이 전하성 및 소수성 아미노산으로 구성된 비정형 펩타이드 태그를 포함하여 자가 조립체를 형성하는 융합 단백질 및 이를 이용하여 재조합 단백질을 정제하는 방법

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7094579B2 (en) * 2002-02-13 2006-08-22 Xoma Technology Ltd. Eukaryotic signal sequences for prokaryotic expression
ATE527371T1 (de) * 2005-03-24 2011-10-15 Biogenerix Ag Expression löslicher, aktiver, eukaryotischer glucosyltransferasen in prokaryotischen organismen
EP2900264A4 (en) * 2012-09-26 2016-05-25 Momenta Pharmaceuticals Inc GLYKOPROTEINZUBEREITUNGEN
EP2821482A1 (en) * 2013-07-05 2015-01-07 Roche Diagniostics GmbH N-terminally truncated glycosyltransferases
EP2824176A1 (en) * 2013-07-11 2015-01-14 Siamed'xpress Methods for producing sialylated therapeutic proteins
EP3083977B1 (en) * 2013-12-20 2018-02-28 F. Hoffmann-La Roche AG Improved recombinant polypeptide production methods
SG11201808457PA (en) * 2016-04-15 2018-10-30 Alpine Immune Sciences Inc Icos ligand variant immunomodulatory proteins and uses thereof
US11674125B2 (en) * 2017-12-18 2023-06-13 The General Hospital Corporation Glycoengineering

Also Published As

Publication number Publication date
AU2021226352A1 (en) 2022-09-29
KR20220145877A (ko) 2022-10-31
EP4110391A1 (en) 2023-01-04
JP2023515554A (ja) 2023-04-13
US20230303984A1 (en) 2023-09-28
CN115605230A (zh) 2023-01-13
CA3173252A1 (en) 2021-09-02
BR112022016948A2 (pt) 2022-11-22
WO2021173797A1 (en) 2021-09-02
MX2022010467A (es) 2022-12-15

Similar Documents

Publication Publication Date Title
CY1124689T1 (el) Trans-αντιγραφοymeno rna
BR112019007433A2 (pt) sistemas de replicon de vírus recombinante e usos dos mesmos
EA201892561A1 (ru) Гибридные белки gdf15 и их применение
CL2022000300A1 (es) Muteínas de interleucina 21 y sus usos para tratar tumores sólidos (divisional de la solicitud no. 202000252)
BR112019007288A2 (pt) proteína heterodimérica biespecífica, composições de ácido nucleico e de vetor de expressão, vetor de expressão, célula hospedeira, e, métodos para produzir proteína heterodimérica biespecífica e para tratar câncer em um paciente
BRPI0716997B8 (pt) proteína ou composição de moléculas de proteína, métodos para produção e uso da mesma
Cesaratto et al. Engineered tobacco etch virus (TEV) protease active in the secretory pathway of mammalian cells
BR112018000477A2 (pt) proteína de ligação de imunoglobulina não natural, composição, uso da proteína de ligação de ig não natural, método de purificação de afinidade de imunoglobulinas, método de geração de uma proteína de ligação de imunoglobulina não natural, molécula de ácido nucleico, vetor, célula hospedeira ou um hospedeiro não humano, e método para a produção de uma proteína de ligação de imunoglobulina não natural
BR112012013330A2 (pt) composições e métodos para aumentar meia vida do soro de proteínas de fusão fc
CO2022013638A2 (es) Enzimas para la sialilación de glicanos
EA202092093A1 (ru) Композиции и способы перепрограммирования tcr с применением слитых белков
BR112019003622A2 (pt) método para produção de uma proteína de fusão.
RU2011117210A (ru) Улучшенные способы рнк-дисплея
EA201590826A1 (ru) Способы очистки арилсульфатазы а
Mueller et al. High level in vivo mucin-type glycosylation in Escherichia coli
CY1120078T1 (el) Διαδικασια παραγωγης και επεξεργασιας του παραγοντα viii και τα παραγωγα του
BR112021025359A2 (pt) Composições de proteína anti-vegf e métodos para a produção das mesmas
BR112017008525A2 (pt) proteína de fusão isolada, e, métodos para tratamento ou alívio de um sintoma de uma doença ou distúrbio, para tratamento ou alívio de uma inflamação ou um sintoma de uma doença ou distúrbio inflamatório e para redução do risco de infecção em um indivíduo.
CL2023001434A1 (es) Muteína de il-2; proteína de fusión; ácido nucleico; vector; célula hospedera; métodos; uso
BR112023003526A2 (pt) Proteínas de fusão de coronavírus imunogênicos e métodos relacionados
BR112021023438A2 (pt) Caracterização de variantes de carga específica de domínio de anticorpos
SV2017005545A (es) Fusiones de variante iii del receptor de factor de crecimiento epidermico-mesotelina y metodos para usar los mismos
BR112022017174A2 (pt) Anticorpo monoclonal isolado, ou uma porção de ligação ao antígeno do mesmo, nucleotídeo, vetor de expressão, célula hospedeira, composição farmacêutica e métodos de tratamento de uma doença alérgica e de um tumor
BR112021018608A2 (pt) Anticorpos para claudina-6 e conjugados de fármaco
BR112022006842A2 (pt) Construtos de igf2 variante